Počet záznamů: 1  

A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer

  1. 1.
    SYSNO ASEP0552718
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevA Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer
    Tvůrce(i) Nounu, A. (GB)
    Greenhough, A. (GB)
    Heesom, K.J. (GB)
    Richmond, R.C. (GB)
    Zheng, J. (GB)
    Weinstein, S.J. (US)
    Albanes, D. (US)
    Baron, J.A. (US)
    Hopper, J.L. (AU)
    Figueiredo, J.C. (US)
    Newcomb, P.A. (US)
    Lindor, N.M. (US)
    Casey, G. (US)
    Platz, E.A. (US)
    Le Marchand, L. (US)
    Ulrich, C.M. (US)
    Li, Ch.I. (US)
    van Duijnhoven, F.J.B. (NL)
    Gsur, A. (AT)
    Campbell, C. T. (US)
    Moreno, V. (ES)
    Vodička, Pavel (UEM-P) RID
    Vodičková, Ludmila (UEM-P) RID
    Brenner, H. (DE)
    Chang-Claude, J. (DE)
    Hoffmeister, M. (DE)
    Sakoda, L.C. (US)
    Slattery, J.M. (US)
    Schoen, R.E. (US)
    Gunter, M.J. (FR)
    Castellví-Bel, S. (ES)
    Kim, H.R. (KR)
    Kweon, S.S. (KR)
    Chan, A.T. (US)
    Li, L. (US)
    Zheng, W. (US)
    Bishop, D.T. (US)
    Buchanan, D.D. (AT)
    Giles, G.G. (AU)
    Gruber, S.B. (US)
    Rennert, G. (IL)
    Stadler, Z.K. (US)
    Harrison, T.A. (US)
    Lin, Y. (US)
    Keku, T.O. (US)
    Woods, M.O. (CA)
    Schafmayer, C. (DE)
    Van Guelpen, B. (SE)
    Gallinger, S. (CA)
    Hampel, H. (US)
    Berndt, S.I. (US)
    Pharoah, P.D.P. (GB)
    Lindblom, A. (SE)
    Wolk, A. (US)
    Wu, A.H. (US)
    White, E. (US)
    Peters, U. (US)
    Drew, D.A. (US)
    Scherer, D. (DE)
    Bermejo, J. L. (DE)
    Williams, A.C. (GB)
    Relton, C.L. (GB)
    Zdroj.dok.Cancer Epidemiology Biomarkers & Prevention. - : American Association for Cancer Research - ISSN 1055-9965
    Roč. 30, č. 3 (2021), s. 564-575
    Poč.str.12 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovaregulatory variation ; follow-up ; instruments ; risk ; association ; expression ; mutations
    Vědní obor RIVEB - Genetika a molekulární biologie
    Obor OECDGenetics and heredity (medical genetics to be 3)
    CEPGAP304/10/1286 GA ČR - Grantová agentura ČR
    NV15-27580A GA MZd - Ministerstvo zdravotnictví
    NV17-30920A GA MZd - Ministerstvo zdravotnictví
    Způsob publikováníOpen access
    Institucionální podporaUEM-P - RVO:68378041
    UT WOS000627591100020
    EID SCOPUS85099407187
    DOI10.1158/1055-9965.EPI-20-1176
    AnotaceBackground: Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk.

    Methods: Human colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labeling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (N = 3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium (N = 31,684) were used as genetic proxies for protein and mRNA expression levels. Two-sample MR of mRNA/protein expression on CRC risk was performed using eQTL/pQTL data combined with CRC genetic summary data from the Colon Cancer Family Registry (CCFR), Colorectal Transdisciplinary (CORECT), Genetics and Epidemiology of Colorectal Cancer (GECCO) consortia and UK Biobank (55,168 cases and 65,160 controls).

    Results: Altered expression was detected for 125/5886 proteins. Of these, aspirin decreased MCM6, RRM2, and ARFIP2 expression, and MR analysis showed that a standard deviation increase in mRNA/protein expression was associated with increased CRC risk (OR: 1.08, 95% CI, 1.03-1.13, OR: 3.33, 95% CI, 2.46-4.50, and OR: 1.15, 95% CI, 1.02-1.29, respectively).

    Conclusions: MCM6 and RRM2 are involved in DNA repair whereby reduced expression may lead to increased DNA aberrations and ultimately cancer cell death, whereas ARFIP2 is involved in actin cytoskeletal regulation, indicating a possible role in aspirin's reduction of metastasis.

    Impact: Our approach has shown how laboratory experiments and population-based approaches can combine to identify aspirin-targeted proteins possibly affecting CRC risk.
    PracovištěÚstav experimentální medicíny
    KontaktLenka Koželská, lenka.kozelska@iem.cas.cz, Tel.: 241 062 218, 296 442 218
    Rok sběru2022
    Elektronická adresahttps://cebp.aacrjournals.org/content/30/3/564
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.